Stifel raised the firm’s price target on Edwards Lifesciences (EW) to $110 from $105 and keeps a Buy rating on the shares, reporting that the firm’s fifty physician TAVR survey results were “highly encouraging for TAVR growth as a whole and Edwards specifically.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $98 from $95 at Piper Sandler
- Edwards Lifesciences price target raised to $95 from $92 at UBS
- Edwards Lifesciences price target raised to $90 from $87 at Baird
- Edwards Lifesciences price target raised to $104 from $103 at Barclays
- Edwards Lifesciences Stock (EW) Falls as FTC Wins Ruling to Block JenaValve Deal